Get the Stockscreener App
935.58
1.98%
-18.94
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $935.58, with a volume of 2.72M.
It is down -1.98% in the last 24 hours and down -8.09% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$954.52
Open:
$945
24h Volume:
2.72M
Relative Volume:
0.87
Market Cap:
$835.81B
Revenue:
$65.18B
Net Income/Loss:
$20.64B
P/E Ratio:
41.42
EPS:
22.5894
Net Cash Flow:
$5.96B
1W Performance:
+4.30%
1M Performance:
-8.09%
6M Performance:
+14.12%
1Y Performance:
+14.34%
1-Day Range:
$930.02
$957.69
1-Week Range:
$877.11
$976.68
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
935.58 | 835.81B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
243.04 | 585.39B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
208.84 | 369.39B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
203.49 | 315.58B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
120.87 | 298.84B | 64.93B | 18.26B | 12.36B | 7.2751 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Frank Rimerman Advisors Boosts Eli Lilly Stock Position - National Today
Mounjaro: Eli Lilly's GLP-1 Powerhouse Driving Weight Loss Revolution and Investor Interest in North - AD HOC NEWS
Eli Lilly and Company $LLY is Tema Etfs LLC's 4th Largest Position - MarketBeat
Elser Financial Planning Boosts Stake in Eli Lilly - National Today
Elser Financial Planning Inc Has $28.18 Million Stake in Eli Lilly and Company $LLY - MarketBeat
Why Novo Nordisk's Pricing Shift Could Unlock a Much Larger Obesity Market - The Motley Fool
How Eli Lilly’s oral GLP-1 could change the obesity drug market - Healthcare Brew
Eli Lilly (LLY) Valuation Check As Foundayo Oral GLP 1 Approval Lifts Obesity Growth Story - simplywall.st
Eli Lilly (LLY) Receives FDA Approval for Foundayo Weight Management Pill - Insider Monkey
Eli Lilly’s LY4060874 Phase 1 Readout: What a Quiet Pipeline Update Means for LLY Investors - TipRanks
Eli Lilly and Company stock: Foundayo approval ignites 2026 boom? - AD HOC NEWS
To celebrate its anniversary, Eli Lilly marks 150 years of everything else - PRWeek
Should You Be Adding Eli Lilly (NYSE:LLY) To Your Watchlist Today? - 富途牛牛
Novo Nordisk Weight Loss Pill Outperforms Eli Lilly Rival in New Clinical Trial Data - TIKR.com
Nisa Investment Advisors Boosts Stake in Eli Lilly - National Today
3,818 Shares in Eli Lilly and Company $LLY Acquired by Fulcrum Capital LLC - MarketBeat
Nisa Investment Advisors LLC Raises Holdings in Eli Lilly and Company $LLY - MarketBeat
Moody Lynn & Lieberson LLC Purchases 2,657 Shares of Eli Lilly and Company $LLY - MarketBeat
Nikulski Financial Inc. Raises Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company (LLY) expands Zepbound access as pricing reforms boost long-term growth outlook - MSN
FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions - Manufacturing Chemist
Eli Lilly Stock (LLY) Opinions on FDA Approval of Foundayo - Moomoo
Eli Lilly to Acquire Centessa Pharmaceuticals for $6.3 Billion - thelec.net
FDA approves Eli Lilly's new weight loss pill with no food restrictions - qz.com
Eli Lilly's Foundayo Pill Approved: Stock Gains, Launch April 6, 2026News and Statistics - IndexBox
Eli Lilly, Novo Nordisk Intensify Competition With Oral Obesity Drugs - thelec.net
Eli Lilly (LLY) Stock Sinks As Market Gains: Here's Why - Yahoo Finance Singapore
Eli Lilly and Company (NYSE:LLY) Shares Down 2%Should You Sell? - MarketBeat
Novo Nordisk: Competing In A Duopoly (TSX:NOVO:CA) - Seeking Alpha
A new weight-loss pill is here, and it could reshape the GLP-1 market - Fast Company
Stocks with rising composite ratings: Eli Lilly - MSN
Explainer: What to Know About Foundayo, Eli Lilly’s New Once-Daily Weight-Loss Pill - U.S. News & World Report
Doctor shares what to know about new weight-loss pill Foundayo - ABC News
Eli Lilly Stock Surges 3.6% on Strong Trading - National Today
What you need to know about Eli Lilly’s Foundayo weight loss pill - houstonchronicle.com
FDA Approves New GLP-1 Weight Loss Pill from Eli Lilly - People.com
Eli Lilly Secures Landmark FDA Approval for Oral Weight-Loss Pill, Sending Shares Soaring - FinancialContent
Eli Lilly’s Foundayo Pill Resets Obesity Portfolio And Valuation Debate - simplywall.st
Eli Lilly launches Zepbound KwikPen on Ro (LLY:NYSE) - Seeking Alpha
Eli Lilly (LLY) Partners with Ro to Launch Zepbound KwikPen Nati - GuruFocus
Lilly is now pharma's top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn't celebrating - drugdiscoverytrends.com
Ro says working with Eli Lilly to launch Zepbound Kwikpen nationwide on its platform - MarketScreener
RO LAUNCHES ELI LILLY'S KWIKPEN®, OFFERING PATIENTS A MORE CONVENIENT WAY TO TAKE ZEPBOUND® - PR Newswire
Bank of America sees Eli Lilly’s Foundayo as preferred oral GLP-1 - Yahoo Finance
Eli Lilly (NYSE:LLY) Tracks Clinical Pipeline Growth In S&P 500 Fund - Kalkine Media
Lilly's Next Empire: A $10 Billion Bet on AI and Neuroscience - MarketBeat
Lilly's obesity pill Foundayo gains early blockbuster forecast as analysts float 5M+ prescriptions in 2026 - Fierce Pharma
Eli Lilly (LLY) to Acquire Centessa Pharmaceuticals in $7.8B Deal - Insider Monkey
Approvals in Hand, Lilly and Novo Obesity Pills Will Battle It Out on Hairline Differences - BioSpace
Wall Street sees multi-billion dollar debut for Lilly's obesity pill despite Novo lead - reuters.com
BofA Securities Raises Price Target on Eli Lilly to $1,294 From $1,293, Maintains Buy Rating - MarketScreener
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.44%
1.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):